Table 1.
Genetic risk and protective effects of APOE genotypes on AD in different population
| Population | Genotype: OR (95% CI) | Reference | |||||
|---|---|---|---|---|---|---|---|
| ε2*2 | ε2*3 | ε2*4 | ε3*3 | ε3*4 | ε4*4 | ||
| Japanese | 1.1 (0.1–17.2) | 0.9 (0.4–2.5) | 2.4 (0.4–15.4) | 1.0 (Ref) | 5.6 (3.9–8.0) | 33.1 (13.6–80.5) | [11] |
| Japanese | NA | 0.7 (0.3–1.6) | NA | 1.0 (Ref) | 3.9 (1.9–8.0) | 21.8 (8.6–55.3) | [13] |
| Caucasians: clinic/autopsy | 0.6 (0.2–2.0) | 0.6 (0.5–0.8) | 2.6 (1.6–4.0) | 1.0 (Ref) | 3.2 (2.8–3.8) | 14.9 (10.8–20.6) | [11] |
| Caucasians: clinic/autopsy | NA | 0.6 (0.3–1.2 | NA | 1.0 (Ref) | 4.3 (3.3–5.5) | 15.6 (10.9–22.5) | [13] |
| Caucasians: autopsy | 0.1 (0.1–0.4) | 0.4 (0.3–0.5) | 2.7 (1.7–4.4) | 1.0 (Ref) | 6.1 (5.–7.4) | 31.2 (16.6–58.8) | [10] |
| Caucasians: population-based | 0.9 (0.3–2.8) | 0.6 (0.5–0.9) | 1.2 (0.8–2.0) | 1.0 (Ref) | 2.7 (2.2–3.2) | 12.5 (8.8–17.7) | [11] |
| Caucasians: population-based | NA | 0.3 (0.2–0.6) | NA | 1.0 (Ref) | 2.8 (2.3–3.5) | 11.8 (7.0–19.8) | [13] |
| African Americans | 2.4 (0.3–22.7) | 0.6 (0.4–1.7) | 1.8 (0.4–8.1) | 1.0 (Ref) | 1.1 (0.7–1.8) | 5.7 (2.3–14.1) | [11] |
| Hispanics | 2.6 (0.2–33.3) | 0.6 (0.3–1.3) | 3.2 (0.9–11.6) | 1.0 (Ref) | 2.2 (1.3–3.4) | 2.2 (0.7–6.7) | [11] |
OR odds ratio, CI confidence interval, NA not available, Ref referece